MedTrace Logo

Real World Assessment of Clinical Outcome Changes -Including Month of Ramadan-for Dapagliflozin in Management of Type II Diabetes Mellitus

NCT02805361 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 511

Last updated 2019-07-15

No results posted yet for this study

Summary

REWARD is an Non Interventional study aims to describe the changes in the clinical outcomes of Type 2 Diabetes Mellitus patients who are treated with Dapagliflozin for a period of one year including the fasting period of Ramadan

Conditions

  • Type II Diabetes Mellitus

Sponsors & Collaborators

Principal Investigators

  • Tarek M. Fiad, MBBCH MD FRCPI FRCP · Endocrinology Division Departemnt of Medicine, SKMC-UAE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-21
Primary Completion
2018-07-13
Completion
2018-07-13

Countries

  • Kuwait
  • United Arab Emirates

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02805361 on ClinicalTrials.gov